Serum interleukin 6 levels as a useful prognostic predictor of clinically amyopathic dermatomyositis with rapidly progressive interstitial lung disease

Modern Rheumatology

Volumn 24, Issue 4, 2014, Pages 633-636

  Nara, Mizuho ^a   Komatsuda, Atsushi ^a   Omokawa, Ayumi ^a   Togashi, Masaru ^a   Okuyama, Shin ^a   Sawada, Ken Ichi ^a   Wakui, Hideki ^a,b  

^a AKITA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b AKITA UNIVERSITY   (Japan)

Author keywords

Anti melanoma differentiation associated gene 5 (MAD5) antibody; Dermatomyositis; Interleukin 6; Interstitial lung disease; Prognostic factor

Indexed keywords

C REACTIVE PROTEIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FERRITIN; FRUCTOSE BISPHOSPHATE ALDOLASE; INTERLEUKIN 6; PREDNISOLONE;

ADULT; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICALLY AMYOPATHIC DERMATOMYOSITIS; COMPARATIVE STUDY; CONTROLLED STUDY; COUGHING; DERMATOMYOSITIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DYSPNEA; ENZYME BLOOD LEVEL; FEMALE; FERRITIN BLOOD LEVEL; FEVER; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL LUNG DISEASE; MALE; MUSCLE WEAKNESS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RASH; RETROSPECTIVE STUDY; SURVIVAL RATE; BLOOD; COMPLICATION; DISEASE COURSE; MIDDLE AGED; MORTALITY;

ADULT; DERMATOMYOSITIS; DISEASE PROGRESSION; FEMALE; HUMANS; INTERLEUKIN-6; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84903689393     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.3109/14397595.2013.844390     Document Type: Article

References (19)

1. Callen JP, Wortmann RL. Dermatomyositis. Clin Dermatol. 2006; 24(5):363-73.
2. Sontheimer RD. Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sin é myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness? J Am Acad Dermatol. 2002;46(4):626-36.
3. Ye S, Chen XX, Lu XY, Wu MF, Deng Y, Huang WQ, et al. Adult clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease: a retrospective cohort study. Clin Rheumatol. 2007;26(10):1647-54.
4. Mukae H, Ishimoto H, Sakamoto N, Hara S, Kakugawa T, Nakayama S, et al. Clinical diff erences between interstitial lung disease associated with clinically amyopathic dermatomyositis and classic dermatomyositis. Chest. 2009;136(5):1341-7.
5. Gono T, Kawaguchi Y, Satoh T, Kuwana M, Katsumata Y, Takagi K, et al. Clinical manifestation and prognostic factor in anti-melanoma diff erentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis. Rheumatology. 2010;49(9):1713-9.
6. Gono T, Sato S, Kawaguchi Y, Kuwana M, Hanaoka M, Katsumata Y, et al. Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Rheumatology (Oxford). 2012;51(9):1563-70.
7. Muro Y, Sugiura K, Hoshino K, Akiyama M. Disappearance of anti-MDA-5 autoantibodies in clinically amyopathic DM/interstitial lung disease during disease remission. Rheumatology (Oxford). 2012;51(5):800-4.
8. Muro Y, Sugiura K, Akiyama M. Limitations of a single-point evaluation of anti-MDA5 antibody, ferritin, and IL-18 in predicting the prognosis of interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Clin Rheumatol. 2013;32(3):395-8.
9. Cao H, Pan M, Kang Y, Xia Q, Li X, Zhao X, et al. Clinical manifestations of dermatomyositis and clinically amyopathic dermatomyositis patients with positive expression of anti-melanoma diff erentiation-associated gene 5 antibody. Arthritis Care Res (Hoboken). 2012;64(10):1602-10.
10. Janka GE. Hemophagocytic syndromes. Blood Rev. 2007;21:245-53.
11. Tristano AG. Macrophage activation syndrome: a frequent but under-diagnosed complication associated with rheumatic diseases. Med Sci Monit. 2008;14(8):RA27-36.
12. World Medical Association Declaration of Helsinki. Available from: http://www.wma.net/en/30publications/10policies/b3/[accessed 22 March 2013].
13. Ethical Guidelines for Epidemiological Research. Available from: http://www.lifescience.mext.go.jp/files/pdf/n796-01.pdf [accessed 22 March 2013].
14. Sato S, Hoshino K, Satoh T, Fujita T, Kawakami Y, Fujita T, Kuwana M. RNA helicase encoded by melanoma diff erentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis. Association with rapidly progressive interstitial lung disease. Arthritis Rheum. 2009;60(7):2193-200.
15. Sun WC, Sun YC, Lin H, Yan B, Shi GX. Dysregulation of the type I interferon system in adult-onset clinically amyopathic dermatomyositis has a potential contribution to the development of interstitial lung disease. Br J Dermatol. 2012;167(6):1236-44.
16. Miyazaki E, Ando M, Muramatsu T, Fukami T, Matsuo O, Nureki S, et al. Early assessment of rapidly progressive interstitial pneumonia associated with amyopathic dermatomyositis. Clin Rheumatol. 2007; 26(3):436-9.
17. Volanakis JE. Human C-reactive protein: expression, structure, and function. Mol Immunol. 2001;38(2-3):189-97.
18. Mimori T, Nakashima R, Hosono Y. Interstitial lung disease in myositis: clinical subsets, biomarkers, and treatment. Curr Rheumatol Rep. 2012;14(3):264-74.
19. Nagasaka K, Harigai M, Tateishi M, Hara M, Yoshizawa Y, Koike T, et al. Efficacy of combination treatment with cyclosporin A and corticosteroids for acute interstitial pneumonitis associated with dermatomyositis. Mod Rheumatol. 2003;13(3):231-8.